Sandoz receives European Commission approval for biosimilar Hyrimoz (R) (adalimumab)

Althoff, E; Lewis, C; Bauman, M

Althoff, E (reprint author), Novartis Global Media Relat, New York, NY USA.

RHEUMATOLOGY, 2019; 58 (2): E43